RedHill Biopharma Ltd. (RDHL) said that it has received two notices of allowance from the U.S. Patent and Trademark Office or USPTO covering opaganib and RHB-107 or upamostat as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus.
The two patents protect opaganib and RHB-107 for the treatment of COVID-19 until at least 2041 once granted, the company said.
The company has also filed for protection under the Patent Cooperation Treaty (PCT) and has the option of applying in the member countries thereof.
The enrollment in opaganib's global phase 2/3 study in hospitalized patients with severe COVID-19 is almost 100% complete.
RHB-107's ongoing Phase 2/3 study is enrolling U.S. non-hospitalized patients with symptomatic COVID-19 that do not require supplemental oxygen.
Both opaganib and RHB-107 are novel COVID-19 therapeutic candidates, in oral pill form, with dual mechanism of action effects. Both are host-targeted and are therefore expected to be effective against emerging viral variants with various mutations in the spike protein, the company said.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.